Recordati S.p.a. · MIL:REC
Recordati — Merger or Acquisition (October 2024)
8 slides from Recordati's merger presentation, Oct 4, 2024
Slide 1: Acquisition of Global Rights to Enjaymo
ACQUISITION OF GLOBAL RIGHTS TO ENJAYMO® Milan, 4 October 2024
Slide 2: Speakers
SPEAKERS Rob Koremans Scott Pescatore Chief Executive Officer Executive VP Rare Diseases 2
Slide 3: Orphan Drug Enjaymo to Further Enhance Global Rare Diseases Franchise
ORPHAN DRUG ENJAYMO® TO FURTHER ENHANCE GLOBAL RARE DISEASES FRANCHISE • Agreement to acquire from Sanofi global rights to Enjaymo® (sutimlimab), subject to regulatory clearances; Only approved targeted product (biologic) to treat cold agglutinin disease (CAD), a rare B-cell lymphoproliferative diso
Slide 4: Enjaymo Serves Unmet Need in Cold Agglutinin Disease (CAD) Market
ENJAYMO® SERVES UNMET NEED IN COLD AGGLUTININ DISEASE (CAD) MARKET CAD OVERVIEW DISEASE BACKGROUND • Rare B-cell lymphoproliferative disorder, a subgroup of autoimmune hemolytic anemia (AIHA) • Caused by autoantibodies secreted by B-cells that bind to erythrocytes leading to their aggregation and de
Slide 5: Enjaymo (sutimlimab)
ENJAYMO® (sutimlimab) Only approved product for CAD PRODUCT PROFILE KEY FINANCIALS • IV treatment launched in 2022 indicated for patients refractory to 1L or with urgent and severe anemia US • Biologic with IP exclusivity until 2036 in U.S. and Japan and 2037 in EU (including PTE); 14% orphan drug e
Slide 6: Financial Summary
FINANCIAL SUMMARY ▪ 2025 Revenue of >€ 150 million; peak sales of ~ € 250-300 million ▪ EBITDA margin accretive to Rare Diseases business as of 2025 KEY FINANCIALS ▪ Non-recurring costs of ~ € 10 million ▪ FY 2024 minimal contribution expected, subject to closing date ▪ Upfront payment of $ 825 mill
Slide 7: Questions & Answers
QUESTIONS & ANSWERS
Slide 8: Company Declarations, Disclaimers and Profile
COMPANY DECLARATIONS, DISCLAIMERS AND PROFILE Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on